ATE264390T1 - Aminoterminal verkürztes mcp-2 als chemokin antagonist - Google Patents

Aminoterminal verkürztes mcp-2 als chemokin antagonist

Info

Publication number
ATE264390T1
ATE264390T1 AT98947553T AT98947553T ATE264390T1 AT E264390 T1 ATE264390 T1 AT E264390T1 AT 98947553 T AT98947553 T AT 98947553T AT 98947553 T AT98947553 T AT 98947553T AT E264390 T1 ATE264390 T1 AT E264390T1
Authority
AT
Austria
Prior art keywords
aminoterminal
chemokine antagonist
truncated mcp
mcp
truncated
Prior art date
Application number
AT98947553T
Other languages
English (en)
Inventor
Paul Proost
Sofie Struyf
Damme Jo Van
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8227408&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE264390(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Applied Research Systems filed Critical Applied Research Systems
Application granted granted Critical
Publication of ATE264390T1 publication Critical patent/ATE264390T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4813—Exopeptidases (3.4.11. to 3.4.19)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • AIDS & HIV (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT98947553T 1997-09-29 1998-09-28 Aminoterminal verkürztes mcp-2 als chemokin antagonist ATE264390T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP97116863A EP0906954A1 (de) 1997-09-29 1997-09-29 Aminoterminalen verkürzten C-C Chemokine als Chemokine Antagonist
EP97122471A EP0905240A1 (de) 1997-09-29 1997-12-19 Aminoterminalen verkürzten C-C-chemokine and als chemokine Antagonist
EP98104216A EP0905241A1 (de) 1997-09-29 1998-03-10 Aminoterminalen verkürzten C-C Chemokine und als Chemokine Antagonist
PCT/EP1998/006142 WO1999016876A1 (en) 1997-09-29 1998-09-28 Amino-terminally truncated mcp-2 as chemokine antagonists

Publications (1)

Publication Number Publication Date
ATE264390T1 true ATE264390T1 (de) 2004-04-15

Family

ID=8227408

Family Applications (3)

Application Number Title Priority Date Filing Date
AT98947553T ATE264390T1 (de) 1997-09-29 1998-09-28 Aminoterminal verkürztes mcp-2 als chemokin antagonist
AT98951476T ATE263242T1 (de) 1997-09-29 1998-09-28 Aminoterminal verkürztes rantes als chemokin antagonist
AT04007579T ATE368742T1 (de) 1997-09-29 1998-09-28 Aminoterminalen verkürzten c-c chemokine und als chemokine antagonist

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT98951476T ATE263242T1 (de) 1997-09-29 1998-09-28 Aminoterminal verkürztes rantes als chemokin antagonist
AT04007579T ATE368742T1 (de) 1997-09-29 1998-09-28 Aminoterminalen verkürzten c-c chemokine und als chemokine antagonist

Country Status (29)

Country Link
US (5) US6905676B2 (de)
EP (6) EP0906954A1 (de)
JP (2) JP4230659B2 (de)
KR (2) KR100560275B1 (de)
CN (3) CN1145693C (de)
AR (2) AR013529A1 (de)
AT (3) ATE264390T1 (de)
AU (2) AU750606B2 (de)
BG (2) BG64757B1 (de)
BR (2) BR9812394A (de)
CA (2) CA2305017A1 (de)
CY (1) CY1110927T1 (de)
CZ (2) CZ299479B6 (de)
DE (3) DE69838188T2 (de)
DK (3) DK1439231T3 (de)
EA (2) EA003940B1 (de)
EE (2) EE200000152A (de)
ES (3) ES2287601T3 (de)
HK (3) HK1062637A1 (de)
HU (2) HU226468B1 (de)
IL (2) IL135352A (de)
NO (2) NO20001584D0 (de)
NZ (3) NZ503235A (de)
PL (2) PL196427B1 (de)
PT (3) PT1021541E (de)
SK (2) SK286439B6 (de)
UA (2) UA73080C2 (de)
WO (2) WO1999016876A1 (de)
ZA (2) ZA988676B (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
US7067117B1 (en) 1997-09-11 2006-06-27 Cambridge University Technical Services, Ltd. Compounds and methods to inhibit or augment an inflammatory response
US6534626B1 (en) 1997-12-01 2003-03-18 The United States Of America As Represented By The Department Of Health & Human Services Chemokine variants
US7238711B1 (en) 1999-03-17 2007-07-03 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
JP2003512843A (ja) * 1999-10-25 2003-04-08 オーロスクレーン エス． エー． 処理されたヒトケモカインのｐｈｃ−１とｐｈｃ−２
EP1167527A1 (de) * 2000-06-22 2002-01-02 Euroscreen S.A. Prozessierte Menschliche Chemokine: PHC-1 und PHC-2
AU2505601A (en) * 1999-11-15 2001-05-30 Wolf-Georg Forssmann Novel use of hcc-2
CA2316405A1 (en) * 2000-05-26 2001-11-26 Ian Clark-Lewis Modulation of inflammation by protease products
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
UA77950C2 (en) * 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
GB2373785A (en) * 2001-03-28 2002-10-02 Rega Inst For Medical Res Truncating chemokines using dipeptidyl peptidase IV
IL162600A0 (en) 2001-12-17 2005-11-20 Applied Research Systems Cc-chemokine mutants as cc-chemokine antagonists
EP1631680A2 (de) * 2003-05-21 2006-03-08 Bayer HealthCare AG Diagnostika und therapeutika für dipeptidylpeptidase iv (dpp4) assoziierte erkrangkungen
DE102005049637A1 (de) * 2005-10-14 2007-04-26 Rheinisch-Westfälische Technische Hochschule Aachen Antagonisten gegen die Interaktion von PF4 und RANTES
JP5624884B2 (ja) 2007-08-02 2014-11-12 ノビミューンエスアー 抗ｒａｎｔｅｓ抗体およびその使用の方法
US20130053257A1 (en) * 2010-02-08 2013-02-28 Paul E. Oran RANTES Multiplexed Assay, RANTES Variants Related to Disease, and RANTES Variants Related to Enzymatice Activity
US9296803B2 (en) 2010-03-11 2016-03-29 Health Research, Inc. Methods and compositions containing Fc fusion proteins for enhancing immune responses
TW201718851A (zh) * 2015-09-18 2017-06-01 通用醫院公司 具有抗化學排斥(anti-fugetactic)性質之經修飾自然殺手細胞及其用途
CN112469430A (zh) 2018-05-28 2021-03-09 日内瓦大学 抑制大脑炎症的方法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11402391B2 (en) 2020-12-21 2022-08-02 Incelldx, Inc. Methods of treating a long-hauler subject for chronic COVID-19 by administering a CCR5 or CCL5 antagonist

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01265099A (ja) 1987-10-08 1989-10-23 Stichting Rega Vzw 抗ｈｉｖ活性をもつ３’，−フルオロプリン−２’，３’−ジデオキシリボシド類
US5739103A (en) * 1993-11-12 1998-04-14 Dana-Farber Cancer Institute Chemokine N-terminal deletion mutations
WO1996017935A2 (en) * 1994-12-08 1996-06-13 Glaxo Group Limited Rantes peptide and fragments and compositions comprising it for treatment of inflammation
WO1997025427A1 (en) * 1996-01-12 1997-07-17 Genetics Institute, Inc. Beta-chemokine, h1305 (mcp-2)
WO1997035982A2 (en) * 1996-03-27 1997-10-02 Icos Corporation Monocyte chemotactic protein-5 materials and methods
FR2748938B1 (fr) * 1996-05-22 1998-07-31 Pasteur Institut Utilisation de molecules antagonistes de chemokines pour leur activite antivirale notamment contre un retrovirus de type vih
US6168784B1 (en) * 1997-09-03 2001-01-02 Gryphon Sciences N-terminal modifications of RANTES and methods of use

Also Published As

Publication number Publication date
DE69822856D1 (de) 2004-05-06
JP4233214B2 (ja) 2009-03-04
DE69822856T2 (de) 2004-08-19
NZ516027A (en) 2003-05-30
EP1439231B1 (de) 2007-08-01
AR013528A1 (es) 2000-12-27
HUP0003505A2 (hu) 2001-02-28
CZ299479B6 (cs) 2008-08-06
US20050220790A1 (en) 2005-10-06
DE69838188D1 (de) 2007-09-13
AU9442098A (en) 1999-04-23
NO20001584L (no) 2000-03-27
IL135352A (en) 2006-08-20
AU750341B2 (en) 2002-07-18
PL339545A1 (en) 2000-12-18
WO1999016877A1 (en) 1999-04-08
AU750606B2 (en) 2002-07-25
CY1110927T1 (el) 2015-06-10
HU226414B1 (en) 2008-11-28
DK1019507T3 (da) 2004-07-19
JP2001518297A (ja) 2001-10-16
UA73081C2 (en) 2005-06-15
NO20001609D0 (no) 2000-03-28
US20050201977A1 (en) 2005-09-15
IL135351A (en) 2006-08-20
CN1233415C (zh) 2005-12-28
HU226468B1 (en) 2008-12-29
EP1019507B1 (de) 2004-03-31
EP0905241A1 (de) 1999-03-31
US7326411B2 (en) 2008-02-05
EA003940B1 (ru) 2003-10-30
EP1019507A1 (de) 2000-07-19
DE69823218D1 (de) 2004-05-19
CZ20001147A3 (cs) 2000-09-13
CZ20001146A3 (cs) 2000-09-13
EE200000151A (et) 2001-02-15
ATE263242T1 (de) 2004-04-15
JP4230659B2 (ja) 2009-02-25
SK4502000A3 (en) 2000-09-12
PT1021541E (pt) 2004-07-30
BG64679B1 (bg) 2005-11-30
BG104266A (en) 2000-11-30
NZ503235A (en) 2002-08-28
ES2215324T3 (es) 2004-10-01
ZA988676B (en) 1999-12-03
US6977071B2 (en) 2005-12-20
ES2287601T3 (es) 2007-12-16
HUP0003563A2 (hu) 2001-02-28
HK1062637A1 (en) 2004-11-19
EP1439231A2 (de) 2004-07-21
NO20001584D0 (no) 2000-03-27
EP0906954A1 (de) 1999-04-07
ES2218860T3 (es) 2004-11-16
DK1439231T3 (da) 2007-11-05
CZ299478B6 (cs) 2008-08-06
WO1999016876A1 (en) 1999-04-08
BG64757B1 (bg) 2006-02-28
JP2001518296A (ja) 2001-10-16
CA2305017A1 (en) 1999-04-08
CA2304827A1 (en) 1999-04-08
ATE368742T1 (de) 2007-08-15
PL339559A1 (en) 2000-12-18
DE69838188T2 (de) 2007-11-22
EE200000152A (et) 2001-02-15
NZ503234A (en) 2002-06-28
CN1145693C (zh) 2004-04-14
KR100542934B1 (ko) 2006-01-11
EP1021541B1 (de) 2004-04-14
PL196427B1 (pl) 2008-01-31
AR013529A1 (es) 2000-12-27
SK286495B6 (sk) 2008-11-06
HUP0003505A3 (en) 2005-11-28
US6905676B2 (en) 2005-06-14
DE69823218T2 (de) 2004-08-26
EP1021541A1 (de) 2000-07-26
PT1439231E (pt) 2007-08-20
CN1490049A (zh) 2004-04-21
EA003942B1 (ru) 2003-10-30
BR9812565A (pt) 2000-08-01
BG104267A (en) 2000-11-30
NO20001609L (no) 2000-03-28
US20030119148A1 (en) 2003-06-26
CN1148447C (zh) 2004-05-05
US20030124677A1 (en) 2003-07-03
AU9747498A (en) 1999-04-23
KR20010024214A (ko) 2001-03-26
SK286439B6 (sk) 2008-10-07
CN1271386A (zh) 2000-10-25
PT1019507E (pt) 2004-06-30
HK1032425A1 (en) 2001-07-20
EA200000379A1 (ru) 2000-10-30
EA200000378A1 (ru) 2000-10-30
DK1021541T3 (da) 2004-08-02
EP1439231A3 (de) 2004-12-22
HUP0003563A3 (en) 2005-11-28
PL197569B1 (pl) 2008-04-30
HK1032426A1 (en) 2001-07-20
KR100560275B1 (ko) 2006-03-10
ZA988675B (en) 1999-11-24
UA73080C2 (en) 2005-06-15
US7338653B2 (en) 2008-03-04
CN1271385A (zh) 2000-10-25
KR20010024213A (ko) 2001-03-26
EP0905240A1 (de) 1999-03-31
SK4512000A3 (en) 2000-09-12
US20050164936A1 (en) 2005-07-28
BR9812394A (pt) 2000-09-12

Similar Documents

Publication Publication Date Title
ATE264390T1 (de) Aminoterminal verkürztes mcp-2 als chemokin antagonist
DE69719354D1 (de) Muscarin-antagonisten
FI971685A0 (fi) Takykiniini-antagonisteja
DE69429861D1 (de) Endothelin-rezeptor-antagonisten
DE59813430D1 (de) Perylenhydrazidimide als Carbonylderivatisierungsreagenzien
DE69626220T2 (de) 3-azetidinylalkylpiperidine oder -pyrrolidine als tachykinin antagonisten
DE69622731T2 (de) Tetrahydrochinoline als nmda antagonisten
DE69616379T2 (de) N-acyl-2-substituierte-4-(benzimidazolyl- oder imidazopyridinyl-substituierte reste)-piperidine als tachykinin antagonisten
ATE240954T1 (de) Oxazolidinone als 5-ht2a-antagonisten
DE69732715D1 (de) Tachykinin antagoniste
DE69735811D1 (de) Piperazinoderivate als neurokinin-antagonisten
NO179550C (no) Tachykinin reseptorantagonister
ATE192428T1 (de) Nitro-benzamides verwendbar als antiarrythmica
ID17678A (id) Turunan-turunan 4-hidroksi-piperidina
FI941118A (fi) Bentsyyli-imidatsopyridiinijohdannainen angiotensiini II reseptoriantagonistina
IL135352A0 (en) Truncated mcp-2 as chemokine antagonist
ATE228997T1 (de) Nitro-benzamid verwendbar als antiarrythmica
KR950027351U (ko) 반목 항타장치
DK0964867T3 (da) Tachykininantagonister
KR950022906U (ko) 쓰레기를 이용한 구축용 구조물
KR970055867U (ko) 브이씨알의 메인베이스 보강구조
SE9702785D0 (sv) Burgertallrik
DE29603863U1 (de) Decke als Multifunktionsdecke
KR980004088U (ko) 보일러의 상판구조
KR980004090U (ko) 보일러의 상판 결합구조

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1021541

Country of ref document: EP

EEFA Change of the company name